Media Summary: During the 2022 ASCO Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Rajni Agarwal, MD, Stanford University, presents on “Radiation and Busulfan-Free Transplant Using JSP191 Antibody ... Metastatic brain tumors originate from other areas of the body and can have a profound impact on the brain. While surgical ...

Dr Doris Hansen At Tandem 2023 Abstract 256 - Detailed Analysis & Overview

During the 2022 ASCO Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Rajni Agarwal, MD, Stanford University, presents on “Radiation and Busulfan-Free Transplant Using JSP191 Antibody ... Metastatic brain tumors originate from other areas of the body and can have a profound impact on the brain. While surgical ...

Photo Gallery

Dr. Doris Hansen at TANDEM 2023: Abstract 256
Dr. Doris Hansen at TANDEM 2023
Dr. Doris Hansen at ASCO 2022: Abstract No. 8042
Dr. Doris Hansen at ASCO 2023: Abstract No. 8012
CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023
Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma
Advancements in Myeloma Treatment: Real World Outcomes and Quality of Life | Doris Hansen, MD
Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results?
The importance of obtaining real-world data
αβ T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplant for Treating Bone Marrow Failure
ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy
Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
Sponsored
Sponsored
View Detailed Profile
Dr. Doris Hansen at TANDEM 2023: Abstract 256

Dr. Doris Hansen at TANDEM 2023: Abstract 256

LIVE from Orlando:

Dr. Doris Hansen at TANDEM 2023

Dr. Doris Hansen at TANDEM 2023

LIVE from

Sponsored
Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

At ASCO

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023

Interview with

Sponsored
Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma

Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma

From #ASH25:

Advancements in Myeloma Treatment: Real World Outcomes and Quality of Life | Doris Hansen, MD

Advancements in Myeloma Treatment: Real World Outcomes and Quality of Life | Doris Hansen, MD

Dr

Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results?

Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results?

During the 2022 ASCO Annual Meeting, the Multiple Myeloma Hub was pleased to speak to

The importance of obtaining real-world data

The importance of obtaining real-world data

Doris

αβ T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplant for Treating Bone Marrow Failure

αβ T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplant for Treating Bone Marrow Failure

Rajni Agarwal, MD, Stanford University, presents on “Radiation and Busulfan-Free Transplant Using JSP191 Antibody ...

ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy

ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy

At ASH 2024,

Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

Join ASTCT and CIBMTR for the

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

At #ASH25,

Managing and treating CRS, neurological toxicity and cytopenias associated with CAR-T therapy

Managing and treating CRS, neurological toxicity and cytopenias associated with CAR-T therapy

Doris Hansen

Toxicities associated with ide-cel in KarMMa

Toxicities associated with ide-cel in KarMMa

Doris

Real-world experience: ide-cel for R/R multiple myeloma

Real-world experience: ide-cel for R/R multiple myeloma

Doris

Coordinating Care for Metastatic Brain Tumors

Coordinating Care for Metastatic Brain Tumors

Metastatic brain tumors originate from other areas of the body and can have a profound impact on the brain. While surgical ...